Abstract
A promising strategy for cancer treatment is adoptive gene therapy / immunotherapy by genetically modifying T lymphocytes with a chimeric receptor (ch-TCR) so that cytotoxic T lymphocytes (CTL) can target and lyse tumors in a MHC-non-restricted manner. It is, however, not clear whether non-MHC-restricted tumor cell recognition by T cells will result in activation- induced apoptosis (AICD). This review discusses the factors that affect the development of AICD or CTL proliferation, and how such factors should be considered in the design of clinical trials using ch-TCR.
Keywords: Antigen-Specific Receptors, Cancer Adoptive Immunotherapy/, anti-CD3, TCR signaling
Current Gene Therapy
Title: Life or Death of T Cells with Antigen-Specific Receptors - Using T Cells for Cancer Adoptive Immunotherapy / Gene Therapy
Volume: 1 Issue: 3
Author(s): L. Ren-Heidenreich and L. G. Lum
Affiliation:
Keywords: Antigen-Specific Receptors, Cancer Adoptive Immunotherapy/, anti-CD3, TCR signaling
Abstract: A promising strategy for cancer treatment is adoptive gene therapy / immunotherapy by genetically modifying T lymphocytes with a chimeric receptor (ch-TCR) so that cytotoxic T lymphocytes (CTL) can target and lyse tumors in a MHC-non-restricted manner. It is, however, not clear whether non-MHC-restricted tumor cell recognition by T cells will result in activation- induced apoptosis (AICD). This review discusses the factors that affect the development of AICD or CTL proliferation, and how such factors should be considered in the design of clinical trials using ch-TCR.
Export Options
About this article
Cite this article as:
Ren-Heidenreich L. and Lum G. L., Life or Death of T Cells with Antigen-Specific Receptors - Using T Cells for Cancer Adoptive Immunotherapy / Gene Therapy, Current Gene Therapy 2001; 1 (3) . https://dx.doi.org/10.2174/1566523013348607
DOI https://dx.doi.org/10.2174/1566523013348607 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Targeting Epigenetic Modifiers in Cancer
Current Medicinal Chemistry Gallium in Cancer Treatment
Current Topics in Medicinal Chemistry Role of Inflammatory Mediators in Angiogenesis
Current Drug Targets - Inflammation & Allergy The Therapeutic Potential of RNA Interference: Novel Approaches for Cancer Treatment
Current Pharmaceutical Biotechnology Resveratrol in Medicinal Chemistry: A Critical Review of its Pharmacokinetics, Drug-Delivery, and Membrane Interactions
Current Medicinal Chemistry SnoN: Bridging Neurobiology and Cancer Biology
Current Molecular Medicine Epigenetics in Medullary Thyroid Cancer: From Pathogenesis to Targeted Therapy
Recent Patents on Anti-Cancer Drug Discovery Ginkgolic Acids Confer Potential Anticancer Effects by Targeting Pro- Inflammatory and Oncogenic Signaling Molecules
Current Molecular Pharmacology Critical Review of the Evidence on 5-Aminosalicilate for Chemoprevention of Colorectal Cancer in Ulcerative Colitis: A Methodological Question
Current Clinical Pharmacology Lignans and Polyphenols of Phyllanthus amarus Schumach and Thonn Induce Apoptosis in HCT116 Human Colon Cancer Cells through Caspases-Dependent Pathway
Current Pharmaceutical Biotechnology Characterization of Cepharanthin Nanosuspensions and Evaluation of Their In Vitro Activity for the HepG2 Hepatocellular Carcinoma Cell Line
Anti-Cancer Agents in Medicinal Chemistry Novel Insights Into c-Src
Current Pharmaceutical Design Angiotensin-I Converting Enzyme Inhibitors as Potential Anti-Angiogenic Agents for Cancer Therapy
Current Cancer Drug Targets Biosynthetic and Metabolic Alterations in Cancer Growth
Current Angiogenesis (Discontinued) Resveratrol and Lifespan in Model Organisms
Current Medicinal Chemistry Conditionally Replicating Adenoviruses for Cancer Treatment
Current Cancer Drug Targets Editorial [Hot Topic: The Application of Systems Biology and Bioinformatics Methods in Proteomics, Transcriptomics and Metabolomics (PART II)]
Protein & Peptide Letters Chemokine Receptors as Targets for Cancer Therapy
Current Pharmaceutical Design Recent Developments in the Pharmacological Properties of 4'-Geranyloxyferulic Acid, a Colon Cancer Chemopreventive Agent of Natural Origin
Current Drug Targets Is there a Role for Epigenetic Enhancement of Immunomodulatory Approaches to Cancer Treatment?
Current Cancer Drug Targets